RAN GTPase and Osteopontin in Pancreatic Cancer.
INTRODUCTION: Pancreatic ductal adenocarcinoma (PDA) has the worst prognosis among cancers, mainly due to the high incidence of early metastases. RAN small GTPase (RAN) is a protein that plays physiological roles in the regulation of nuclear transport and microtubule spindle assembly. RAN was recently shown to mediate the invasive functions of the prometastatic protein osteopontin (OPN) in breast cancer cells. We and others have shown previously that high levels of OPN are present in PDA. In this study, we analyzed the expression and correlation of RAN with OPN in human pancreatic lesions, and explored their regulation in PDA cell lines.
METHODS: Real time PCR was used to analyze RAN and OPN mRNA levels in PDA, adjacent non-malignant, and benign pancreatic tissues. Expression levels were correlated with survival and different clinicopathological parameters using different statistical methods. Transient transfection studies using OPN and RAN plasmids, and knockdown experiments using siRNA were used to examine their mutual regulation.
RESULTS: OPN and RAN levels highly correlated with each other (p
CONCLUSIONS: The high levels of RAN in PDA and its correlation with OPN and with perineural invasion suggest that RAN may contribute to PDA metastasis and progression through the induction of OPN. RAN's role in the regulation of OPN in PDA is unique and could provide potential novel therapeutic strategies to combat PDA aggressiveness.
Published In/Presented At
Saxena, S., Gandhi, A., Lim, P. W., Relles, D., Sarosiek, K., Kang, C., Chipitsyna, G., Sendecki, J., Yeo, C. J., & Arafat, H. A. (2013). RAN GTPase and Osteopontin in Pancreatic Cancer. Pancreatic disorders & therapy, 3(1), 113. https://doi.org/10.4172/2165-7092.1000113
Medicine and Health Sciences
Department of Medicine